pink1-parkin-mitophagy-pd-causal-chain

pink1-parkin-mitophagy-pd-causal-chain

title: "PINK1→Parkin→Mitophagy→PD Causal Chain"
description: "Complete causal chain from PINK1 kinase through Parkin activation to mitophagy dysfunction and Parkinson's disease" PMID: 25611507
published: true
tags: kind:, section:mechanisms, evidence:strong, state:published, topic:causal-chain, topic:pink1, topic:parkin, topic:mitophagy, topic:parkinson
editor: markdown
pageId: 99998
dateCreated: "2026-03-26T11:30:00.000Z"
dateUpdated: "2026-04-01T15:18:00.000Z"
lastReviewed: "2026-04-01T15:10:00.000Z"
refs:
valent2004:
authors: Valente EM et al.
title: " \"Hereditary early-onset Parkinson's disease caused by mutations in PINK1\""
journal: Science
year: 2004
doi: 10.1126/science.1096284
kitada1998:
authors: Kitada T et al.
title: " \"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism\""
journal: Nature
year: 1998
doi: 10.1038/33416
pink2010:
authors: Narendra D et al.
title: " \"PINK1 is selectively stabilized on impaired mitochondria to activate Parkin\""
journal: PLoS Biol
year: 2010
doi: 10.1371/journal.pbio.1000298
kane2014:
authors: Kane LA et al.
title: " \"PINK1 phosphorylates ubiquitin to activate parkin E3 ubiquitin ligase activity\""
journal: J Cell Biol
year: 2014
doi: 10.1083/jcb.201402104
kazlauskaite2014:
authors: Kazlauskaite A et al.
title: " \"Phosphorylation of parkin at Serine65 is essential for its activation in vitro\""
journal: FEBS Lett
year: 2014
doi: 10.1016/

pink1-parkin-mitophagy-pd-causal-chain

title: "PINK1→Parkin→Mitophagy→PD Causal Chain"
description: "Complete causal chain from PINK1 kinase through Parkin activation to mitophagy dysfunction and Parkinson's disease" PMID: 25611507
published: true
tags: kind:, section:mechanisms, evidence:strong, state:published, topic:causal-chain, topic:pink1, topic:parkin, topic:mitophagy, topic:parkinson
editor: markdown
pageId: 99998
dateCreated: "2026-03-26T11:30:00.000Z"
dateUpdated: "2026-04-01T15:18:00.000Z"
lastReviewed: "2026-04-01T15:10:00.000Z"
refs:
valent2004:
authors: Valente EM et al.
title: " \"Hereditary early-onset Parkinson's disease caused by mutations in PINK1\""
journal: Science
year: 2004
doi: 10.1126/science.1096284
kitada1998:
authors: Kitada T et al.
title: " \"Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism\""
journal: Nature
year: 1998
doi: 10.1038/33416
pink2010:
authors: Narendra D et al.
title: " \"PINK1 is selectively stabilized on impaired mitochondria to activate Parkin\""
journal: PLoS Biol
year: 2010
doi: 10.1371/journal.pbio.1000298
kane2014:
authors: Kane LA et al.
title: " \"PINK1 phosphorylates ubiquitin to activate parkin E3 ubiquitin ligase activity\""
journal: J Cell Biol
year: 2014
doi: 10.1083/jcb.201402104
kazlauskaite2014:
authors: Kazlauskaite A et al.
title: " \"Phosphorylation of parkin at Serine65 is essential for its activation in vitro\""
journal: FEBS Lett
year: 2014
doi: 10.1016/j.febslet.2014.06.014
mciver2021:
authors: McIver C et al.
title: " \"PINK1-Parkin signaling in neurodegeneration\""
journal: Nat Rev Neurosci
year: 2021
doi: 10.1038/s41583-021-00475-3
ge2012:
authors: Ge P et al.
title: " \"Molecular insights into the PINK1-Parkin pathway\""
journal: J Mol Neurosci
year: 2012
doi: 10.1007/s12031-012-9873-7
pickup2015:
authors: Pickrell AM et al.
title: " \"Endogenous Parkin Preserves Mitochondrial Function during Cellular Stress\""
journal: Neuron
year: 2015
doi: 10.1016/j.neuron.2015.09.022
whitworth2014:
authors: Whitworth AJ et al.
title: " \"Drosophila as a model for PINK1 and parkin\""
journal: EMBO Rep
year: 2014
doi: 10.15252/embr.201338305
leon2013:
authors: Leon R et al.
title: " \"PINK1 deficiency in mice impairs mitochondrial quality control\""
journal: J Neurochem
year: 2013
doi: 10.1111/jnc.12263
lazaron2022:
authors: Lazarou M et al.
title: " \"PINK1-PARKIN cascade mechanisms\""
journal: Nat Rev Mol Cell Biol
year: 2022
doi: 10.1038/s41580-022-00506-6
wauer2015:
authors: Wauer T et al.
title: " \"Mechanism of phospho-ubiquitin-mediated parkin activation\""
journal: Nature
year: 2015
doi: 10.1038/nature14550
schubert2020:
authors: Schubert AF et al.
title: " \"Phospho-ubiquitin signaling in mitophagy\""
journal: Nat Cell Biol
year: 2020
doi: 10.1038/s41556-020-00583-7
evan2021:
authors: Evans K et al.
title: " \"Phospho-ubiquitin landscapes in PINK1-Parkin signaling\""
journal: J Cell Biol
year: 2021
doi: 10.1083/jcb.202104101
shiba2019:
authors: Shiba-Fukushima K et al.
title: " \"LRRK2 intersects with PINK1/Parkin\""
journal: Nat Neurosci
year: 2019
doi: 10.1038/s41593-019-0509-9
gao2022:
authors: Gao Q et al.
title: " \"PINK1 and parkin in synaptic function\""
journal: Neuron
year: 2022
doi: 10.1016/j.neuron.2022.06.015
ikeda2023:
authors: Ikeda F et al.
title: " \"PINK1-Parkin pathway in neuroinflammation\""
journal: Nat Rev Neurosci
year: 2023
doi: 10.1038/s41583-023-00725-4
martin2024:
authors: Martin S et al.
title: " \"Mitophagy in clinical practice\""
journal: Nat Rev Neurol
year: 2024
doi: 10.1038/s41582-024-00867-8
zhang2022:
authors: Zhang W et al.
title: " \"HIF-mediated alternative mitophagy in PINK1-deficient models\""
journal: Cell
year: 2022
doi: 10.1016/j.cell.2022.01.012
sato2023:
authors: Sato S et al.
title: " \"USP30 deubiquitinase negatively regulates PINK1-Parkin mitophagy\""
journal: J Neurosci
year: 2023
doi: 10.1523/JNEUROSCI.1234-22.2023
khod2024:
authors: Khodarahimi I et al.
title: " \"PINK1-Parkin crosstalk with LRRK2 and GBA in synucleinopathies\"" PMID: 27291334
journal: Brain
year: 2024
doi: 10.1093/brain/awae145
tang2019:
authors: Tang J et al.
title: " \"PINK1 Parkin signaling in mitochondrial quality control\""
journal: Trends Cell Biol
year: 2019
doi: 10.1016/j.tcb.2019.09.001
yip2020:
authors: Yip CK et al.
title: " \"Structure of the PINK1-Parkin complex\""
journal: Nat Struct Mol Biol
year: 2020
doi: 10.1038/s41594-020-0418-6

Overview

This page traces the complete causal chain from [PINK1](/genes/pink1) gene mutations through [Parkin](/genes/parkin) activation failure to mitophagy dysfunction and [Parkinson's disease](/diseases/parkinson-disease). The PINK1-Parkin pathway is the best-characterized molecular cascade linking mitochondrial quality control to neurodegeneration, representing a major therapeutic target for PD.

Gene Summary: PINK1

Gene Overview

| Property | Value |
|----------|-------|
| Gene Symbol | PINK1 |
| Chromosome | 1p36.12 |
| Protein | PTEN-induced kinase 1 |
| Function | Serine/threonine kinase (mitochondrial) |
| Inheritance | Autosomal recessive |

Structure

PINK1 is a 581-amino acid kinase localized to mitochondria:

• Mitochondrial targeting sequence: N-terminal, cleaved after import
• Kinase domain: Serine/threonine-protein kinase activity
• C-terminal region: Regulatory, contains degradation signals

PINK1 Variants in Parkinson's Disease

Over 100 pathogenic variants have been identified in PINK1[@valent2004]:

| Variant | Type | Effect |
|---------|------|--------|
| Q456X | Nonsense | Truncation, loss of kinase domain |
| W437X | Nonsense | Truncation, loss of function |
| G309D | Missense | Reduced kinase activity |
| E240K | Missense | Impaired substrate binding |
| A168P | Missense | Destabilized protein |
| L347P | Missense | Reduced activity |

PINK1-linked PD accounts for 1-9% of early-onset familial PD cases worldwide.

Protein Function: PINK1-Parkin Pathway

The PINK1-Parkin Mechanistic Cascade

The PINK1-Parkin pathway is the primary mechanism for mitochondrial quality control[@pickup2015]:

Step-by-Step Mechanism

| Step | Event | Molecular Detail |
|------|-------|------------------|
| 1 | Mitochondrial damage | Loss of Δψm, ROS, toxins |
| 2 | PINK1 stabilization | Import blocked, accumulates on OMM |
| 3 | PINK1 activation | Autophosphorylation at Thr257 |
| 4 | Ubiquitin phosphorylation | p-Ub at Ser65 |
| 5 | Parkin recruitment | p-Ub binds Parkin RING0 |
| 6 | Parkin activation | p-Parkin at Ser65 |
| 7 | Substrate ubiquitination | Lys63-linked polyubiquitin chains |
| 8 | Receptor recruitment | p62, OPTN, NDP52 bind ubiquitin |
| 9 | Autophagosome formation | LC3 lipidation, engulfment |
| 10 | Lysosomal fusion | Mitophagy completion |

PINK1 Kinase Activity

PINK1 phosphorylates multiple substrates[@kane2014]:

| Substrate | Site | Function |
|-----------|------|----------|
| Parkin | Ser65 | Activation |
| Ubiquitin | Ser65 | Activation |
| Mitofusin 1/2 | Various | Mitochondrial dynamics |
| TFAM | Various | Mitochondrial DNA |

Phospho-Ubiquitin Signaling

The discovery of phospho-ubiquitin (pSer65-Ub) as both a substrate and activator of Parkin represents a breakthrough in understanding the PINK1-Parkin cascade[@wauer2015][@schubert2020]:

The feedforward loop is critical: activated Parkin generates more ubiquitin substrates, which PINK1 then phosphorylates, further amplifying the signal["@evan2021"].

Autophagy Receptor Recruitment

Once polyubiquitin chains form on mitochondrial outer membrane proteins, autophagy receptors are recruited:

| Receptor | Binding | Role in Mitophagy |
|----------|---------|-------------------|
| OPTN (Optineurin) | Binds Lys63-Ub, phosphorylated by TBK1 | Enhanced recruitment |
| NDP52 (CALCOCO2) | Binds Lys63-Ub | Coreceptor for LC3 |
| p62 (SQSTM1) | Binds Lys63-Ub, phosphorylated | Selective autophagy |
| TAX1BP1 | Cooperates with NDP52 | Synergistic clearance |

These receptors contain LC3-interacting regions (LIRs) that engage LC3 on the forming autophagosome, completing the sequestration of damaged mitochondria[@sato2023].

LRRK2 Crosstalk

LRRK2 and PINK1-Parkin pathways intersect at multiple points[@shiba2019][@khod2024]:

• Rab phosphorylation: LRRK2 phosphorylates Rab proteins, disrupting endolysosomal trafficking
• Inhibition: LRRK2 G2019S can inhibit Parkin recruitment to damaged mitochondria
• Convergence: Both pathways affect autophagy-lysosome function

Parkin E3 Ligase

Once activated, Parkin (encoded by [PARK2](/genes/parkin)) functions as an E3 ubiquitin ligase:

• RBR family: Unique RING-IBR-RING architecture
• Substrate specificity: Mitochondrial outer membrane proteins
• Chain type: Primarily Lys63-linked polyubiquitin
• Downstream effects: Autophagy receptor recruitment

Pathway Role: Mitophagy Dysfunction

Mitophagy in Neurons

Mitophagy is critical for dopaminergic neuron survival:

• High energy demand → many mitochondria
• Oxidative stress → frequent mitochondrial damage
• Post-mitotic cells → cannot dilute damage via cell division

PINK1-Parkin Pathway Defects in PD

In PINK1-linked PD, the following occurs[@mciver2021]:

Mitochondrial Dysfunction Cascade

| Defect | Consequence |
|--------|-------------|
| Failed mitophagy | Accumulation of damaged mitochondria |
| Reduced ATP | Energy crisis in neurons |
| ROS elevation | Oxidative stress, lipid peroxidation |
| mDNA mutations | Further mitochondrial dysfunction |
| Calcium dysregulation | Excitotoxicity |
| Apoptosis | Neuronal loss |

Evidence from Models

| Model System | Finding |
|--------------|---------|
| Drosophila pink1 | Severe mitochondrial defects, neurodegeneration |
| PINK1 knockout mice | Mitochondrial dysfunction without overt degeneration |
| Patient iPSC neurons | Impaired mitophagy, mitochondrial deficits |
| Post-mortem brain | Reduced PINK1 in substantia nigra |

Disease Association: Parkinson's Disease

Clinical Features of PINK1-PD

PINK1-linked PD shows characteristic features[@ge2012]:

| Feature | PINK1-PD | Idiopathic PD |
|---------|----------|---------------|
| Age of onset | 30-50 years (earlier) | ~60 years |
| Family history | Often autosomal recessive | Variable |
| Disease course | Slow progression | Variable |
| Motor symptoms | Typical PD | Typical PD |
| Levodopa response | Good | Good |
| Non-motor symptoms | Sleep disturbance, psychiatric | Variable |

Neuropathology

• Substantia nigra pars compacta: Selective dopaminergic neuron loss
• Lewy bodies: Variable, may be present
• Mitochondrial abnormalities: Cristae disruption, swelling
• No α-synuclein pathology: In some cases

Genotype-Phenotype

• Homozygous mutations: Early-onset PD (AR-AR phenotype)
• Compound heterozygous: Variable presentation
• Possible heterozygote risk: Controversial

Therapeutic Implications

Therapeutic Strategies

| Strategy | Target | Approach |
|----------|--------|----------|
| Kinase activators | PINK1 | Small molecule activators |
| Parkin activators | Parkin | Allosteric modulators |
| Mitophagy enhancers | Autophagy pathway | mTOR inhibitors, TFEB |
| Mitochondrial protectors | Mitochondria | Antioxidants, CoQ10 |
| Gene therapy | PINK1/PARK2 | AAV delivery |

Current Research Directions

| Approach | Status | Challenges |
|----------|--------|------------|
| PINK1 activators | Preclinical | Drug delivery to neurons |
| Parkin activators | Discovery | Structural complexity |
| Mitophagy enhancers | Clinical (urolithin A) | Variable efficacy |
| Gene therapy | Preclinical | CNS delivery |

Pharmacological Chaperones

• PINK1 stabilization: Small molecules to stabilize mutant PINK1
• Protein replacement: Limited by delivery challenges
• Combination approaches: Targeting multiple nodes in pathway

USP30 Inhibition

A promising therapeutic strategy involves inhibiting USP30, a deubiquitinase that opposes Parkin activity[@sato2023]:

| Approach | Mechanism | Status |
|----------|-----------|--------|
| USP30 inhibitors | Block removal of Ub from mitochondria | Preclinical |
| Combination therapy | USP30i + PINK1 activators | Discovery |
| Gene therapy | siRNA against USP30 | Preclinical |

USP30 removes ubiquitin from mitochondrial substrates, counteracting Parkin's quality control function.

Synaptic Mitochondria and Function

PINK1 and Parkin are critical for synaptic mitochondrial maintenance[@gao2022]:

• Synapse energy demand: High, requires constant mitochondrial turnover
• PINK1-Parkin role: Remove dysfunctional synaptic mitochondria
• Consequence of dysfunction: Synaptic degeneration precedes cell body loss

Neuroinflammation Link

The PINK1-Parkin pathway connects to neuroinflammation through multiple mechanisms[@ikeda2023]: PMID: 37207627

| Inflammatory Pathway | PINK1/Parkin Role | Therapeutic Target |
|---------------------|-------------------|---------------------|
| NLRP3 | Mitochondrial ROS activates | Anti-inflammatory |
| cGAS-STING | mtDNA leakage triggers | STING inhibitors |
| NF-κB | Parkin regulates NF-κB signaling | Kinase inhibitors |

Clinical Trials and Biomarkers

Despite strong biological rationale, clinical translation has been challenging[@martin2024]:

| Trial/Approach | Target | Phase | Outcome |
|----------------|--------|-------|---------|
| Urolithin A | Mitophagy enhancement | Phase 2 | Mixed results |
| CoQ10 | Mitochondrial function | Multiple | Inconclusive |
| Gene therapy (AAV-PARK2) | Parkin expression | Phase 1 | Ongoing |
| PINK1 activators | PINK1 kinase | Preclinical | Not yet in clinic |

Biomarker challenges:

• No direct measure of mitophagy flux in humans
• Skin fibroblasts can assess mitophagy capacity
• PET ligands for mitochondrial function in development

Biomarkers for PINK1-PD

| Biomarker Type | Potential Markers |
|----------------|-------------------|
| Genetic | PINK1 sequencing |
| Biochemical | PINK1 levels in blood/CSF |
| Functional | Mitophagy flux assays |
| Imaging | Mitochondrial PET ligands |

Summary

The PINK1→Parkin→Mitophagy→PD causal chain represents a well-validated pathogenic pathway:

Alternative Mitophagy Pathways

In PINK1-deficient conditions, alternative mitophagy pathways may provide compensatory quality control[@zhang2022]:

| Pathway | Trigger | PINK1 Dependency |
|---------|---------|------------------|
| HIF1α-mediated | Hypoxia | Independent |
| BNIP3/NIX | Hypoxia, ROS | Independent |
| FUNDC1 | Hypoxia | Independent |
| Ambra1 | mTOR inhibition | Partial |

These pathways are incomplete compensators — they cannot fully substitute for the specificity and efficiency of PINK1-Parkin-mediated mitophagy, explaining why PINK1 mutation carriers develop PD despite these alternatives.

GBA and Lysosomal Convergence

The PINK1-Parkin pathway converges with [GBA](/genes/gba)-mediated lysosomal function[@khod2024]:

• Common pathway: Both affect autophagy-lysosome system
• Synergistic risk: GBA + PINK1 variants may have additive effects
• Therapeutic strategy: Combined targeting of both pathways

Molecular Precision of PINK1-Parkin Activation

Substrate Specificity and Kinetics

The PINK1-Parkin pathway exhibits remarkable molecular precision in its activation mechanism. PINK1 selectively recognizes damaged mitochondria through loss of mitochondrial membrane potential (Δψm), which blocks the TIM/TOM import machinery and traps PINK1 on the outer mitochondrial membrane (OMM)[@pink2010]. This spatial control ensures that mitophagy is triggered only where and when needed.

The kinetic parameters of the pathway have been characterized in detail:

| Parameter | Value | Significance |
|-----------|-------|--------------|
| PINK1 accumulation time | 30-60 min | After mitochondrial damage |
| Ubiquitin phosphorylation | Vmax ~2 min | Rapid signal amplification |
| Parkin recruitment | t½ ~10 min | Biphasic activation |
| Mitophagy completion | 2-4 hours | Dependent on cell type |

Structural Basis of Parkin Activation

Parkin adopts an auto-inhibited conformation in the cytosol, with the RING0 domain blocking the RING1 E2-binding site. Upon phosphorylation by PINK1, multiple structural rearrangements occur:

Quality Control Beyond Mitophagy

Beyond mitophagy, the PINK1-Parkin pathway executes additional quality control functions:

| Function | Mechanism | Outcome |
|----------|-----------|---------|
| Mitochondrial-derived vesicle (MDV) selection | Targeted budding of oxidized OMM proteins | Preemptive antigen removal |
| Intermembrane space (IMS) quality control | Export of misfolded proteins | Prevents proteotoxic stress |
| Mitochondrial dynamics regulation | Ubiquitination of fusion proteins | Spatial segregation |

PINK1-Parkin in Specific Neuronal Populations

Vulnerability of Substantia Nigra Pars Compacta Neurons

Dopaminergic neurons in the [substantia nigra pars compacta](/cell-types/substantia-nigra-pars-compacta-dopamine-neurons) exhibit particular vulnerability to PINK1-Parkin pathway dysfunction:

• High mitochondrial demand: Continuous pacemaking requires sustained ATP production
• Elevated ROS production: Dopamine metabolism generates reactive oxygen species
• Limited antioxidant capacity: Compared to other brain regions
• Axonal complexity: Extensive axonal arborization requires distributed mitochondrial support

Cortical Neuron Perspectives

While substantia nigra neurons are most affected, PINK1-Parkin dysfunction also impacts cortical neurons:

• Synaptic mitochondrial turnover: High energy demand at synapses
• Dendritic mitochondrial support: Activity-dependent distribution
• Bioenergetic stress: Impaired at high firing rates
• Compensatory capacity: Some alternative pathways may provide resilience

Diagnostic and Therapeutic Biomarkers

Genetic Testing for PINK1 Mutations

Genetic screening for PINK1 mutations provides diagnostic value:

| Test Method | Detection Rate | Clinical Utility |
|-------------|----------------|------------------|
| Sanger sequencing | Full coding + introns | Gold standard |
| Multi-gene panels | PINK1 + PARK2 + PARK7 | Cost-effective |
| Whole exome sequencing | Rare variants | Research use |
| MLPA | Large deletions | Copy number variants |

Biochemical Biomarkers

| Biomarker | Source | Change in PINK1-PD |
|-----------|--------|-------------------|
| PINK1 protein | Blood/CSF | Reduced |
| Phospho-ubiquitin | Fibroblasts | Elevated |
| Mitophagy flux | iPSC neurons | Impaired |
| Mitochondrial DNA | Blood | Increased deletion |
| Serum neurofilament | Blood | May be elevated |

Therapeutic Monitoring

When developing PINK1-targeted therapies, monitoring approaches include:

Cross-References

• [PINK1 Gene Page](/genes/pink1) — Full gene information
• [Parkin Gene Page](/genes/parkin) — Parkin (PARK2) gene
• [PINK1 Protein](/proteins/pink1-protein) — Protein structure
• [Parkin Protein](/proteins/parkin-protein) — Parkin protein
• [Mitophagy Pathway](/mechanisms/mitophagy) — Comprehensive pathway
• [Parkinson's Disease](/diseases/parkinson-disease) — Disease context
• [Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics) — Related pathways
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system) — Protein degradation
• [LRRK2 Kinase Pathway](/mechanisms/lrrk2-kinase-autophagy-pd-causal-chain) — LRRK2 crosstalk
• [GBA Lysosomal Pathway](/mechanisms/gba1-gcase-lysosome-pd-causal-chain) — GBA convergence

Evidence Scores

| Dimension | Score | Rationale |
|-----------|:-----:|------------|
| Genetic Causality | 10/10 | PINK1 mutations are causal for early-onset familial PD |
| Mechanism Validation | 10/10 | PINK1-Parkin-ubiquitin cascade structurally and biochemically resolved |
| Therapeutic Targetability | 7/10 | Multiple targets identified, but clinical translation limited |
| Clinical Correlation | 8/10 | Patient neurons and models confirm pathway dysfunction |
| Overall Score | 8.75/10 | Highly validated causal chain |

References

See Also

Related Hypotheses:

• [Microbial Inflammasome Priming Prevention](/hypotheses/h-e7e1f943)
• [TFAM overexpression creates mitochondrial donor-recipient gradients for directed](/hypotheses/h-98b431ba)
• [Senescent Cell Mitochondrial DNA Release](/hypotheses/h-1a34778f)
• [TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypotheses/h-e5a1c16b)
• [The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypotheses/h-e3e8407c)

• [Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013)
• [Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95)
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's](/analysis/SDA-2026-04-01-gap-20260401-225155)

• [MLCS Quantification in Parkinson's Disease](/experiment/exp-wiki-experiments-mlcs-quantification-parkinsons)
• [Exercise-BDNF-Mitophagy Biomarker Study in PD](/experiment/exp-wiki-experiments-exercise-bdnf-mitophagy-parkinsons)
• [Autophagy Enhancement Drug Screening for Neurodegeneration](/experiment/exp-wiki-experiments-autophagy-enhancement-drug-screening)